| Title |
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
|
|---|---|
| Published in |
Targeted Oncology, February 2018
|
| DOI | 10.1007/s11523-018-0550-9 |
| Pubmed ID | |
| Authors |
Mehran Makvandi, Edouard Dupis, Jonathan W. Engle, F. Meiring Nortier, Michael E. Fassbender, Sam Simon, Eva R. Birnbaum, Robert W. Atcher, Kevin D. John, Olivier Rixe, Jeffrey P. Norenberg |
| Abstract |
Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for cancer treatment. When coupled with monoclonal antibodies, peptides, small molecules, or nanoparticles, the excellent cytotoxic capability of α-particle emissions has generated a strong interest in exploring targeted α-therapy in the pre-clinical setting and more recently in clinical trials in oncology. Multiple obstacles have been overcome by researchers and clinicians to accelerate the development of targeted α-therapies, especially with the recent improvement in isotope production and purification, but also with the development of innovative strategies for optimized targeting. Numerous studies have demonstrated the in vitro and in vivo efficacy of the targeted α-therapy. Radium-223 (223Ra) dichloride (Xofigo®) is the first α-emitter to have received FDA approval for the treatment of prostate cancer with metastatic bone lesions. There is a significant increase in the number of clinical trials in oncology using several radionuclides such as Actinium-225 (225Ac), Bismuth-213 (213Bi), Lead-212 (212Pb), Astatine (211At) or Radium-223 (223Ra) assessing their safety and preliminary activity. This review will cover their therapeutic application as well as summarize the investigations that provide the foundation for further clinical development. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 143 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 143 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 26 | 18% |
| Researcher | 26 | 18% |
| Student > Master | 17 | 12% |
| Student > Bachelor | 10 | 7% |
| Other | 9 | 6% |
| Other | 17 | 12% |
| Unknown | 38 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 38 | 27% |
| Medicine and Dentistry | 13 | 9% |
| Physics and Astronomy | 12 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Agricultural and Biological Sciences | 6 | 4% |
| Other | 21 | 15% |
| Unknown | 46 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2023.
All research outputs
#3,203,047
of 24,226,848 outputs
Outputs from Targeted Oncology
#35
of 576 outputs
Outputs of similar age
#73,031
of 447,217 outputs
Outputs of similar age from Targeted Oncology
#3
of 14 outputs
Altmetric has tracked 24,226,848 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 576 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,217 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.